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(54) IN SITU PREPARATION OF DRUG ELUTING STENTS WITH BIOCOMPATIBLE PHOTO 
CROSSLINKED HYDROGELS
(57) Disclosed herein is a stent system adapted for
being implanted in a body cavity or vessel, such as a
blood vessel, a ureteral duct or an intestine, the stent
system comprising a stent mesh, a catheter extending
through the stent mesh, a biocompatible solution adapted
for forming photo-crosslinked hydrogels when exposed
to radiation, an inner balloon positioned around the cath-
eter, and an outer balloon positioned around the inner
balloon, wherein the outer balloon contains the biocom-
patible solution, the biocompatible solution filling up the
space between the inner balloon and the outer balloon.
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Description
[0001] The invention relates to a stent system adapted
for being implanted in a body cavity or body vessel, such
as a blood vessel, an esophageal tract, a biliary or ure-
teral ducts or an intestine section. The stent system com-
prises a stent mesh having a hollow cylindrical shape
expandable in diameter from an initial stent diameter to
an expanded stent diameter, wherein enclosed inside
the stent mesh and comprised further in the stent system
are a catheter and balloon system containing solution
capable of forming a hydrogel.
BACKGROUND
[0002] Stenosis is a stricture, or narrowing of the lumen
of a physiologic tubular structure or duct enabling the
flow of physiological fluid like blood, urine, bile, food bolus
or product of digestion (chime and chyle). The reduction
of the lumen diameter may be related to the presence of
cholesterol plaques (in blood vessels), bile duct stones,
chronic inflammation syndromes (inflammatory bowel
disease) and malignant disorders (esophageal,stomach,
pancreatic, upper intestine and colorectal cancer).
[0003] Strictures in the colon represent a complication
of inflammatory bowel disease which interests 1.4 million
only in the US. The cause of inflammatory bowel disease
is still unknown but is occurs as an abnormal immune
response which misidentifies ordinary substances like
food, bacteria, and other material trafficking the intestine
as harmful pathogens and directs immune cells towards
the intestinal epithelium producing local inflammation.
[0004] The broadest diseases belonging to inflamma-
tory bowel disease category are Ulcerative Colitis and
Crohn’s Disease. The prevalence rate of inflammatory
bowel disease has been reported to be up to 396 per
100,000 persons. Across the world, the highest incidents
occur in the US, Canada, the UK, and Scandinavia.
[0005] Colon strictures are recurrent complications for
30% of patients with Crohn’s Disease. More than 80%
of patients with Crohn’s Disease have are submitted to
at least one surgical resection in the first 10 years of
diagnosis, the operation is due to intestinal strictures. In
40% of the patients, relapse and intestinal strictures need
secondary operations. With recurrent resections patients
suffer of short bowel syndrome, because intestinal length
and function are lost permanently.
[0006] The pathophysiology of the inflammatory bowel
disease related intestinal stricture has not been clarified
yet; it is believed that they result either from persistent
inflammation or from fibrosis. When the stenosis is an
effect of inflammation the current therapies consist of
amino salicylates (sulfazine, mesalamine, olsalazine,
balsalazide) and corticosteroid (methylprednisolone,
prednisone, budesonide, hydrocortisone) which at
present are administered either by the oral or rectal
routes. These therapeutics are usefull in the early stage
of the disease but they only mitigate the symptoms whilst
they do not act on the causes of inflammation.
[0007] For patients with advanced disease conditions
and for whom the other treatments failed, immunosup-
pressive and immunoregulatory agents can be consid-
ered a therapeutic option. Major drugs in this category
are Azathioprine (Imuran®, Azasan®), 6 mercaptopurine
(6MP®, Purinethol®), Cyclosporine A (Sandimmune®,
Neoral®) and Tracrolimus (Prograf®) available both for
oral and parenteral delivery. These active compounds
have been used for Crohn’s Disease over the last 25
years for decreasing, delaying or preventing strictures.
Typically, they exhibit extremely low bioavailability and
at the same time can entail harmful over-suppression of
immune response increasing the risk of infections and
toxicity. Moreover the use of these immunomodulators
with such formulations does not change risk of develop-
ing intestinal strictures. A clever drug delivery system is
here needed to optimize the drug concentration at the
site of action and enhance the drug bioavailability by en-
hancing drug aqueous solubility and promoting drug ab-
sorption by means of adequate pharmacological carriers.
[0008] The newest class of biological therapeutics, ap-
proved by FDA for treatment of inflammatory bowel dis-
eases include antibodies and peptides targeting the spe-
cific substances involved in the overactive immune re-
sponse. To this group belong Infliximab (Remicade®,
Adalimumab (Humira®), Certolizumabpegol (Cimzia®),
Natalizumab (Tysabri®), Golimumab (Simponi®). Humi-
ra and Remicade were reported to be amongst the top
15 bestselling drugs of 2012. So far all the biologics are
available for parenteral administration only because
there are no available formulations which can preserve
the therapeutic activity of these labile compounds from
the aggressive environment of the digestive system.
[0009] For orally dosed therapeutics the availability to
the diseased sites exhibits large inter-individual differ-
ences (between 35 and 75%) resulting in variable clinical
response rates mainly for factor connected to intestinal
physiology of the disease: (i) prolonged intestinal transit
time (compared to healthy patients), (ii) intraluminal pH
profiles, (iii) variable distribution pattern of inflamed mu-
cosa. Indeed an effective therapeutic action can be
achieved only with defined drug concentrations in the
mucosa, considering that degradation and deactivation
by the intestinal microflora as well as systemic circulation
of the drug should be limited to reduce the potential for
adverse effects. On the other hand, the major disadvan-
tage of the biologics administered by injections is that
they lack of any targeting ability meaning that by the sys-
temic circulation they travel throughout the body sup-
pressing the immune system. In the ideal case the active
ingredient should be released in proximity to the affected
areas and execute topically its therapeutic action.
[0010] Along with the pharmacological therapies,
Crohn’s Disease related anastomotic strictures up to 4-5
cm long have been treated by endoscopic balloon dilation
with long term success the in 41%-63% of patients since
1970s, but the remaining group of patients still requires
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repeated dilation and surgery.
[0011] To reduce this high risk of recurrence, the use
of stents had been proposed. A stent is a cylindrical med-
ical device with a reticular structure with expandable
properties which is inserted in the body cavity to widen
a narrow or stenosed lumen and maintain its physiolog-
ical shape and dimension. Currently, stents are being
increasingly used in blood vessels, esophagus, renal and
biliary ducts and in the gastrointestinal and colonic tracts.
[0012] Over the last 30 years, material and design of
stents with gastrointestinal applications, referred as en-
teral stents, have undergone dramatic changes. Materi-
als proposed for these stents were initially plastic, then
metallic alloys until the last generation of biodegradable
stents which is currently under clinical studies. Enteral
stents are meant to produce endoscopic stricturoplasty
with a prolonged dilation of the stenosis compared to the
endoscopic balloon. The main drawbacks of these de-
vices which so far limited their clinical use are the possible
stent migration and perforation of the surrounding muco-
sa. Covered stents have been introduced to minimize
tissue ingrowth through the mesh but are associated with
higher occurrence of migration.
[0013] The geometry of the stent coating has a strong
impact on stent spontaneous movements, and a control
of the coating is very important feature. Another possible
function of the coating is the local release of active in-
gredient towards the surrounding intestinal tract and in
the whole colonic region. Drug eluting stents (DES) have
been initially introduced in angioplasty procedure to re-
duce proliferation of smooth muscle cells and vessel wall
recoil following the insertion of stents in region obstructed
by cholesterol plaques. As for other implantation sites,
drugeluting enteral stents are likely becoming available
in the near future. Experts in the field agreed to identify
the most important features for DES in the following: (i)
homogeneous coverage of the drug along all stent sur-
faces; (ii) retention and protection of the drug on the stent
when exposed to routine handling; (iii) prevention of the
loss of drug during processing and stent implantation;
(iv) prevention of overdosing from non-uniform drug dis-
tribution or immediate burst release of the total drug pay-
load; (v) local, targeted, short-term, low-dose drug re-
lease.
[0014] Drug eluting stents currently under study are
loaded with small molecule chemotherapeutic and anti-
proliferative drugs by pre-insertion deposition by micro
pipetting and drying. This procedure requires particular
ability in the specialized personnel in the execution of
stent positioning, as a critical aspect is represented by
loss of substance during the handling. Moreover, prior to
administrating novel active ingredients, like the above-
mentioned peptide and antibody based- compounds
(and the eventual carrier in which they are encapsulated),
have to be maintained in an aqueous environment with
defined conditions of pH, temperature and ionic strength,
in order to maintain their therapeutic activity. The stent
deposition procedures so far explored are unlikely appli-
cable for such labile therapeutics. The coating distribu-
tion on the stent structure is also an important issue: the
drug elution should preferably be oriented towards the
cavity walls and release the therapeutic agent unidirec-
tionally while the release to the lumen side should be
avoided to reduce drug loss and unspecific adsorption
by healthy tissues. To fulfill a unidirectional drug elution
stents with special nanoliter microreservoir open on the
external surface were proposed. Besides the high costs
such devices suffer of low capacity for the drug payload
and rather complicated loading procedure are required.
[0015] As a result, an in situ deposition of the liquid
coating after the stent positioning would allow to extend
optimal physico-chemical conditions for labile formula-
tions until prior to administration, and high control of the
drug dose for the minimal handling is required. Such a
coating would maintain intact the therapeutic efficacy of
the most novel formulations (promoting internalization of
the therapeutic in the diseased cells) and would be an-
chored to the stent mesh in such a way that reduces stent
migration and limits the drug release towards the lumen
side.
[0016] When local occlusions occurs in a body cavity
or body vessel such as e.g. a blood vessel, an esopha-
geal tract, a ureteral duct or an intestine section, biocom-
patible stents are often inserted into the body cavity/ves-
sel as treatment.
[0017] A stent with a small cross-section may be in-
serted into the body cavity/vessel/lumen by means of a
catheter and expended at the correct location inside the
body cavity/vessel by use of an expanding balloon posi-
tioned inside the mesh.
[0018] Alternatively, a stent may be formed in situ as
shown in EP0836448B1, which discloses a curable fibre
composite stent, which, upon formation in situ inside a
selected region of a body lumen, serves to support the
lumen without significant obstruction to blood flow. The
stent is made up of a biocompatible fibrous material which
is coated, impregnated, filled, or otherwise treated with
a curable material so that the fibre composite can be
suitably shaped to support a portion of a body lumen and
then cured to maintain the shape. The fibre composite
and the curable material may be biodegradable so that
the stent does not become a permanent part of the body.
The polymer stent may be cured using UV light which is
inserted through the catheter/balloon system in situ.
[0019] Alternatively, a stent may be formed inside a
body cavity as disclosed in WO2011/130536A2, where
liquid biodegradable material are formed as stents inside
the body by means of a catheter, a balloon system com-
prising three balloons, and UV light. In
WO2011/130536A2, two balloons are expanded where-
by a cavity is formed into which a polymer material is
introduced. A third balloon is used for obtaining a specific
shaping of the polymer material, and UV light is used
afterwards for illuminating the polymer solution to cure
the polymer. The polymer stents formed in
WO2011/130536A2 are biodegradable and will therefore
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degrade over time.
[0020] EP0431046B1 also discloses a polymer stent
fabricated and tested in vivo by placing polymer material
on a balloon, which is inserted and shaped inside the
human body cavity. Afterwards the polymer is illuminated
with UV light to obtain a more rigid solid structure by
curing the polymer material. The stent is made from a
biodegradable polymeric materials such as e.g. a poly-
lactone or a polyanhydride in a form of solid matrix ca-
pable of maintaining the size and shape and proving me-
chanical support to the tissue around it.
DESCRIPTION OF THE INVENTION
[0021] The invention relates in a first aspect of the in-
vention to a stent system adapted for being implanted in
a body cavity or vessel. Examples of body cavities/ves-
sels are a blood vessel, a ureteral duct, an esophageal
tract, an intestine section, or similar. Thus, by body cavity
or body vessel is meant all types of channels or lumens
inside the human body ranging from small blood vessels
to large intestines.
[0022] The stent system comprising a stent mesh with
a stent structure, the stent mesh having a hollow cylin-
drical shape expandable in diameter from an initial stent
diameter to an expanded stent diameter, the hollow cy-
lindrical shape comprising a plurality of openings in be-
tween the mesh structure. The stent mesh may also be
expandable or shrinkable in a longitudinal direction.
[0023] Enclosed inside the stent mesh and comprised
further in the stent system are:
• a catheter extending through the stent mesh, the
catheter being adapted for containing an optical fibre
providing radiation, e.g. in the wavelength range be-
tween 10-800 nm;
• a biocompatible solution adapted for forming photo-
crosslinked hydrogels when exposed to radiation
from the optical fibre extending through the catheter,
the biocompatible solution comprising one or more
monomers, and/or one or more oligomers, and/or
one or more polymers;
• an inner balloon positioned around the catheter;
• an outer balloon positioned around the inner balloon,
wherein the outer balloon contains the biocompatible
solution, the biocompatible solution filling up the
space between the inner balloon and the outer bal-
loon.
[0024] Upon expansion of the inner balloon, the stent
mesh may expand to obtain the expanded stent diameter,
and the outer balloon breaks whereby the biocompatible
solution is distributed in the openings in between the stent
mesh structure and around the stent mesh structure. By
around is also meant the space between the stent mesh
and the body cavity/vessel.
[0025] By photo-crosslinked is also included photo-re-
ticulation - i.e. any linking reaction between the biocom-
patible solution comprising one or more monomers,
and/or one or more oligomers, and/or one or more poly-
mers.
[0026] Alternatively, the stent mesh may be self-ex-
pandable, possibly expanding prior to the expansion of
the balloons.
[0027] Upon radiation from the optical fibre, the bio-
compatible solution distributed in the openings in be-
tween the stent mesh structure and around the stent
mesh structure is adapted to create a coating layer
around the stent mesh.
[0028] The stent system will most often be implanted
in an inflamed section of the body cavity/vessel, or a sec-
tion, which needs further support in order to avoid col-
lapse of the cavity/vessel.
[0029] The invention relates in a second aspect of the
invention to a method for implanting a hydrogel coated
stent in a body cavity or body vessel, such as a blood
vessel, a ureteral duct or an intestine section. The method
comprising the steps of:
• inserting a stent system according to the above into
a body cavity or body vessel;
• inserting an optical fibre adapted for providing light
in the wavelength range between 10 nm - 800 nm
inside the stent system if the optical fibre is not al-
ready inserted inside the stent system;
• expanding the inner balloon to a pre-determined size
such that the stent mesh obtains a first predeter-
mined size at which the outer balloon breaks and the
biocompatible solution is distributed in the openings
in between the stent mesh structure and around the
stent mesh structure;
• shaping the stent mesh to match the tissue in the
surrounding body cavity or body vessel by expanding
the inner balloon to obtain the expanded diameter;
• irradiating the biocompatible solution distributed in
the openings in between the stent mesh structure
and around the stent mesh structure with light in the
wavelength range between 10 nm - 800 nm from the
optical fibre thereby creating a reticulated polymeric
hydrogel serving as a coating of the stent mesh, and
• removing the optical fibre and catheter from the body
cavity or body vessel thereby leaving the hydrogel
coated stent in the body cavity or body vessel.
[0030] The invention relates in a third aspect of the
invention to a method for implanting a hydrogel coated
stent in a body cavity or body vessel, such as a blood
vessel, a ureteral duct or an intestine, the method com-
prising the steps of:
- inserting a stent system according to the above into
a body cavity or body vessel;
- inserting an optical fibre adapted for providing light
in the wavelength range between 10 nm - 800 nm
inside the stent system if the optical fibre is not al-
ready inserted inside the stent system;
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- expanding the stent mesh to match the body cavity
or body vessel;
- expanding the inner balloon to a pre-determined at
which the outer balloon breaks and the biocompati-
ble solution is distributed in the openings in between
the stent mesh structure and around the stent mesh
structure;
- possibly shaping the stent mesh to match the tissue
in the surrounding body cavity or body vessel by ex-
panding the inner balloon to obtain the expanded
diameter;
- irradiating the biocompatible solution distributed in
the openings in between the stent mesh structure
and around the stent mesh structure with light in the
wavelength range between 10 nm - 800 nm from the
optical fibre thereby creating a reticulated polymeric
hydrogel serving as a coating of the stent mesh, and
- removing the optical fibre and catheter from the body
cavity or body vessel thereby leaving the hydrogel
coated stent in the body cavity or body vessel.
[0031] By body cavity or body vessel is meant all types
of channels or lumens inside the human body ranging
from small blood vessels to large intestines.
[0032] By the biocompatible solution being distributed
in the openings in between the stent mesh structure and
around the stent mesh structure is meant that the solution
surrounds the stent mesh structure on the inside and the
outside as well in the openings between the mesh struc-
ture.
[0033] The optical fibre may provide radiation in the
ultra violet wavelength range or at both higher or lower
wavelength ranges, e.g. between 10-800 nm. For exam-
ple, the optical fibre may provide radiation in the ultra
violet wavelength range between 10-450 nm.
[0034] In one or more embodiments, the optical fibre
may provide radiation in the wavelength range between
100-450 nm, or between 150-400 nm, or between
300-400 nm.
[0035] Alternatively, the optical fibre may provide radi-
ation in the visible wavelength range between 400-800
nm. The wavelength range extending a bit into the near
infrared and the ultra violet wavelength range.
[0036] In one or more embodiments, the optical fibre
may provide radiation in the wavelength range between
450-700 nm, or between 400-500 nm, or between
500-600 nm, or between 600-700 nm.
[0037] In yet alternative embodiments, the optical fibre
may provide radiation in the infrared wavelength range
above 700 nm, e.g. between 700-2000 nm. In one or
more embodiments, the optical fibre may provide radia-
tion in the wavelength range between 700-800 nm, or
between 800-1200 nm, or between 1100-2000 nm.
[0038] The choice of wavelength is made to ensure
that a cross-linked hydrogel coating is obtained as well
as to ensure that as little damage to the surrounding tis-
sue/vessel wall is introduced due to radiation from the
radiation source in situ.
[0039] By the above stent system and method is ob-
tained a system/method, which allows a practitioner to
insert a biocompatible stent inside a body cavity/vessel
of a patient and in situ form a coating layer around the
stent mesh. This coating layer has a number of highly
beneficial properties, one of them being that it is a hy-
drogel coating layer having a biosimilar nature, thus be-
ing biocompatible. The biocompatibility ensures an im-
proved adhesion between the stent mesh and the sur-
rounding tissue/vessel wall in the body cavity/vessel. Fur-
thermore, the hydrogel coating layer reduces the occur-
rence of spontaneous movement of stent after insertion
in the body cavity/vessel, which is a problem very fre-
quently observed with e.g. well-known enteral stents. Al-
so, the hydrogel coating layer around the stent mesh pre-
vents tissue perforation by sharp fibres in the stent mesh.
The hydrogel coating layer further offers a mechanical
resistance to reocclusion of the lumen caused by cell
regrowth and/or fibrotic tissue growth and/or immuno-
genic reactions. Also, the hydrogel coating reduces the
occurrence of restenosis. Further, the hydrogel coating
is suitable for drug/therapheutic substance delivery pur-
poses. For example, is it possible to incorporate lipo-
somes and other colloidal formulations in their functional
state.
[0040] In one or more embodiments, the stent mesh is
adapted for expanding to obtain the expanded stent di-
ameter upon expansion of the inner balloon. Alternative-
ly, the stent mesh may have self-expanding features.
[0041] Depending on the size of the body cavity/vessel,
which the stent system is to be inserted in, the size of
the stent mesh and the coating layer formed around the
mesh will vary. Overall, the stent mesh may have an initial
stent mesh diameter of between 2-30 mm. Similarly,
overall the coating layer may have a thickness between
0.05 mm - 5 mm,
If the stent system is for being inserted into a blood vessel,
the stent mesh is normally rather small with an initial non-
expanded stent diameter of 2-5 mm, which is expanded
in situ to fit inside the blood vessel. Thus, in one or more
embodiments, the stent mesh has an initial stent diam-
eter of 2-5 mm.
[0042] In one or more embodiments, the coating layer
has a thickness between 0.1 mm - 10 mm.
[0043] In one or more embodiments, the coating layer
has a thickness between 0.1 mm - 1 mm.
[0044] In one or more embodiments, the coating layer
has a thickness between 1 mm - 100 mm.
[0045] In one or more embodiments, the coating layer
has a thickness between 1 mm - 10 mm.
[0046] If the stent system is for being inserted into a
larger body channel such as e.g. a ureteral duct, the stent
mesh will normally need to be larger than the stent mesh-
es used for a blood vessel. Such a stent mesh may have
an initial non-expanded stent diameter of 8-10 mm, which
is expanded in situ up to size matching the inside the
ureteral duct. Thus, in one or more embodiments, the
stent mesh has an initial stent diameter of 8-10 mm.
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[0047] In one or more embodiments, the coating layer
has a thickness between 10 mm - 100 mm.
[0048] In one or more embodiments the coating layer
has a thickness between 10 mm - 500 mm.
[0049] In one or more embodiments the coating layer
has a thickness between 1 mm - 1 mm.
[0050] In one or more embodiments the coating layer
has a thickness between 1 mm - 5 mm.
[0051] The coating layer thicknesses between 1-5 mm
are usually more suitable for large stent mesh sizes such
as those used in the intestine part. The stent mesh for
use in the intestine will normally have an initial non-ex-
panded stent diameter of 2-30 mm, which is expanded
in situ up to match the inside of the intestine. Thus, in
one or more embodiments, the stent mesh has an initial
stent diameter of 2-30 mm.
[0052] The biocompatible solution comprises one or
more monomers, and/or one or more oligomers, and/or
one or more polymers. Examples of suitable polymers
are polyvinylpyrrolidone, sodium alginate, synthetic pol-
ymers, or naturally occurring polymers modified to be
cross-linkable upon exposure to radiation from the optical
fibre.
[0053] In one or more embodiments, the one or more
polymers is polyvinylpyrrolidone.The hydrogel with pol-
yvinylpyrrolidone used in an example of the invention
have proven to have antifouling properties.
[0054] In one or more embodiments, the biocompatible
solution is a hydrogel solution having a three dimensional
crosslinked polymer network with amphiphilic compo-
nents.
[0055] In one or more embodiments, the biocompatible
solution further comprises one or more additional sub-
stances. The additional substance may -when exposed
to radiation - serve the purpose of photo initiating/acti-
vating the hydrogel polymerization and/or cross-linking
reaction to form the hydrogel coating layer. Thus, the
stent system may further comprise a photo-initia-
tor/cross-linker in connection with/contained inside the
biocompatible solution. The hydrogel coating layer may
in this manner be formed by a radical or ionic cross-linking
or polymerization reaction initiated by the photo initiator
when the photo initiator is exposed to radiation from the
optical fibre.
[0056] In one or more embodiments, the biocompatible
solution comprises two or more polymers, wherein at
least one of the polymers is cross-linkable upon exposure
to radiation between 10 nm - 800 nm. The cross-likable
polymer may serve as photo initiator.
[0057] In one or more embodiments, the photo initiator
is a water soluble photo initiator.
[0058] In one or more embodiments, the additional
substance is in a concentration between 0.1-1.5% wt.,
or between 0.5-1.5% wt., or between 0.7-1.0% wt., such
as e.g. 0.9% wt.
[0059] In one or more embodiments, the one or more
additional substances is selected from the group of: hy-
drogen peroxide, benzoyl peroxide, acetophenone, ben-
zoin, 2,2-dimethoxy-2-phenylacetophenone, dibenzoyl,
disulphides, diphenyldithiocarbonate, 2,20-azobisisobu-
tyronitrile, camphorquinone, eosin Y, triethanolamine,
2,2-bis[4-(2-hydroxy-3-methacryloxypropoxy)-phe-
nyl]propane, lithium phenyl-2,4,6-trimethylbenzoylphos-
phinate, (1-[4-(2-Hydroxyethoxy)-phenyl]-2-hydroxy-2-
methyl-1-propane-1-one, 2,20-Azobis[2-methyl-N-(2-
hydroxyethyl)propionamide, (1-hydroxycyclohexyl)-phe-
nylmethanone.
[0060] The additional substance may be hydrogen per-
oxide which in small concentrations only has an ignorable
toxic effect on the tissue in the body cavity/vessel.
[0061] In one or more embodiments, one or more bio-
active components are comprised in the stent system.
[0062] The one or more bioactive components may in-
clude one or more of: a bioactive agent, a bioactive prin-
ciple, a bioactive compound, a bioactive molecule, a bi-
oactive drug, a therapeutic agent, a therapeutic principle,
a therapeutic compound, a therapeutic molecule, and a
therapeutic drug.
[0063] In one or more embodiments, the one or more
bioactive components is a bioactive component for pre-
venting that the immune response in the body is activat-
ed. If this happens, in worse case scenario, the body
might try to reject the stent mesh.
[0064] In one or more embodiments, the one or more
bioactive components is a bioactive component for pre-
venting that the tissue in the body cavity/vessel is injured
due to the stent mesh.
[0065] In one or more embodiments, the one or more
bioactive components is a bioactive component for pre-
venting inflammation or similar inside the body.
[0066] In one or more embodiments, the one or more
bioactive components is a bioactive component for post-
poning that the immune response in the body is activated.
If this happens, in worse case scenario, the body might
try to reject the stent mesh.
[0067] In one or more embodiments, the one or more
bioactive components is a bioactive component for post-
poning inflammation or similar inside the body.
[0068] In one or more embodiments, the one or more
bioactive components is a therapeutically active compo-
nent for postponing a disease, and inflammation or sim-
ilar. inside the body.
[0069] In one or more embodiments, the one or more
bioactive components is a therapeutically active compo-
nent for treating a disease, and inflammation or similar
inside the body.
[0070] This allows for using the stent system for deliv-
ering both 1) a bioactive component, which prevents re-
jection of the stent or inflammation, which may result in
the formation of scar tissue around the stent, and 2) at
the same time delivering a drug or similar, which reduc-
es/eliminates inflammation or cures a disease in or
around the body cavity/vessel, which the stent system is
inserted into.
[0071] In one or more embodiments, a first and a sec-
ond bioactive component is included in the stent system
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such that at least a prevention of the stent being rejected
is obtained at the same time as a drug for therapeutic
purposes is delivered to the tissue around the stent.
[0072] In one or more embodiments, the one or more
bioactive components is a synthetic or a natural com-
pound of a molecular weight ranging from 100 to 500.000
Da, such as from 1.000 to 500.000 Da, or such as from
10.000 to 500.000 Da, or such as from 100 to 10.000 Da,
or such as from 100 to 1.000 Da.
[0073] The smaller bioactive components having an
average weight ranging from 100 to 1.000 Da exhibit also
poor solubility in water, and often have issues with per-
meability in the biological tissue. For such components
it is difficult to reach the target tissue with a sufficient
therapeutic concentration without the use of a stent sys-
tem according to the invention.
[0074] The larger molecules, like macromolecules
having an average weight ranging from 1000 to 500.000
Da, are normally unstable due to a more fragile structure.
Further, the large macromolecules normally have per-
meability issues and are unlikely to get absorbed without
a system that forces them to stay in proximity to the target
tissue such as the coating described in this invention.
Specific delivery and distribution of macromolecules to
an exact location in the body before they start to degrade,
are methabolized or cleared or lose their bio-relevant ac-
tivity are normally very difficult if not impossible without
the use of a stent system according to the invention.
[0075] To enhance the availability of fragile macromol-
ecules the site of release should be in close proximity to
the target tissue as it is obtained from the hydrogel coat-
ing in this invention. Both the dispersion of small hydro-
phobic therapeutic compounds in aqueous environment
and of the internalization of the therapeutic macromole-
cule in the targeted cells is provided by a clever drug
delivery system further to be comprised in the biocom-
patible solution forming the stent coating upon photo-
reticulation / photo-crosslinking.
[0076] Thus, the stent system disclosed herein can be
advantageously used for delivering bioactive compo-
nents of all kind of sizes.
[0077] The one or more bioactive components may in
one or more embodiments be contained inside colloidal
formulations. An example of a colloidal formulations in-
cludes colloidal drug delivery system (DDS) such as li-
posomes. Liposomes are a specific colloidal drug deliv-
ery system (DDS) where the drug is complexed or en-
capsulated inside a spherical lipid nano vesicular carrier
suspended in an aqueous phase. In such a DDS, the
drug compound (may it be hydrophobic, hydrophilic, a
small and big molecule) is protected from the liquid rea-
gents constituting the hydrogel solution. How fast the
DDS is released form the hydrogel coating to the tissue
in the body cavity/vessel depends on the DDS used
and/or on the hydrogel coating structural properties. In
this manner, controlled release of different drug compo-
nents can be obtained by using different DDS and or
hydrogel coatings. Thus, the therapeutic formulation may
be released by the hydrogel coating over time in a con-
trolled manner. The drug is normally not affected or de-
activated by the radiation from the optical fibre due to the
use of the nano vesicular carrier. The nano vesicular car-
rier may be spherical and formed by lipids and sur-
factants.
[0078] The degree of crosslinking of the hydrogel coat-
ing may be controlled by the light intensity/irradiation time
or by adding different photo initiators and/or photo
crosslinking agents and different polymers to the solution
and/or changing their respective concentrations. In turn
this allows for a control of the release of the bioactive
compounds towards the body cavity/vessel. The release
may be controlled such that an amount of the bioactive
agent is released towards the centre of the body cavi-
ty/vessel from where the bioactive agent, e.g. a drug,
may be flushed by flow of the body fluid stream, e.g. the
blood stream. Alternatively, the release may be control-
led such that it is primarily directed to the cavity/vessel
walls of the body cavity/vessel, whereby only a very small
amount is flushed by flow of the body fluid stream, e.g.
the blood stream. Alternatively, the release may be con-
trolled such that the entire amount of drug payload stored
inside the hydrogel coating is released to the target tissue
within the needed therapeutic ranges of concentration
and time.
[0079] For example, a therapeutic formulation may up-
on radiation be fixed inside an aqueous medium retained
in a hydrogel three dimensional crosslinked polymer net-
work serving as the stent coating. This ensures intact
and functional properties for the delivery purpose of the
therapeutic agent.
[0080] In one or more embodiments, one or more drug
components in the DDS is a hydrophobic drug molecule.
[0081] In one or more embodiments, one or more drug
components in the DDS is a hydrophilic drug molecule.
[0082] In one or more embodiments, the one or more
bioactive components, possibly comprised inside the col-
loidal formulation, are comprised in the biocompatible
solution.
[0083] Alternatively or supplementary, in one or more
embodiments, the one or more bioactive components,
possibly comprised inside the colloidal formulation, are
contained inside the micro reservoirs in the stent mesh.
The stent mesh may be micro fabricated.
[0084] The hydrogel coating may have a three dimen-
sional crosslinked polymer network with amphiphilic
components having entrapped in its three dimensional
structure a colloidal formulation containing bioactive
agents comprising synthetic or natural polymers which
are proteins or mixtures thereof.
[0085] The stent mesh may be made from a biodegrad-
able material. This is advantageous if the stent is meant
to dissolve inside the patient over time.
[0086] Alternatively, the stent mesh is made from bio-
compatible and/or biodegradable metal. This is very use-
ful if it is critical that the body cavity/vessel remains di-
lated, as a metal mesh will retain its structure and not
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collapse over time. Examples of suitable biocompatible
metals includes titanium alloys, zinc or zinc alloys, cobalt-
chromium alloys, magnesium or magnesium alloys, and
stainless steel.
BRIEF DESCRIPTION OF THE DRAWINGS
[0087]
Figures 1 a-b show a stent system according to the
invention.
Figures 2a-f show the implantation of a stent system
according to the invention.
Figure 3 shows the concentration of liposomes la-
belled with fluorescein which are released over time
by different hydrogels specimens composed by a
single polymer constituent or by a blend of two pol-
ymer constituents in different concentrations.
Figure 4 shows the nano scale structure of a hydrogel
network observed with transmission electron micro-
scopy.
DESCRIPTION OF PREFERRED EMBODIMENTS
[0088] Figure 1 shows an example of the invention,
where the circle marked in figure 1 a is the enlargement
shown in figure 1b. In figure 1a, a stent system 100 adapt-
ed for being implanted in a body cavity/vessel 102 as
shown figures 2a-e is shown. The stent system 100 will
most often be implanted in an stenosed/inflamed section
of the body cavity/vessel 102 to restore its physiological
diameter section, which needs further support in order
to avoid recollapse of the cavity/vessel after implantation.
[0089] The stent system 100 comprises a stent mesh
104 having a hollow cylindrical shape expandable in di-
ameter from an initial stent diameter to an expanded stent
diameter. In figures 2a-e, the expansion and the implan-
tation and in situ coating of the stent 104 are illustrated.
As can be seen in figure 1b, the hollow cylindrical shape
of the stent mesh comprising a plurality of openings 105
in between the mesh structure.
[0090] As also shown in figure 1b, enclosed inside the
stent mesh 104 and comprised further in the stent system
100 is a catheter 106 extending through the stent mesh
104. The catheter 106 has an inner diameter which is
large enough for allowing an optical fibre to extend there
through. The optical fibre may be included in the catheter
106 upon delivery of the stent system 100 or may be a
separate fibre, which the medical practitioner inserts
through the catheter 106 prior to insertion of the stent
system 100 in a human body cavity/vessel. Thus, in the
figures the reference number 106 refers both to a catheter
without/before an optical fibre extends there through and
a catheter containing an optical fibre. The optical fibre
may provide radiation in the ultra violet wavelength range
or at both higher or lower wavelength ranges, e.g. be-
tween 10-800 nm.
[0091] Surrounding the catheter 106 is a balloon sys-
tem including an inner balloon 108 positioned directly
around the catheter 106 and an outer balloon 110 posi-
tioned around the inner balloon 108. In between the two
balloons is a space filled with a biocompatible solution
112, which can form reticulated hydrogels, e.g. photo-
crosslinked hydrogels, when exposed to radiation from
the optical fibre extending through catheter 106.
[0092] The biocompatible solution 112 comprising one
or more monomers, and/or one or more oligomers, and/or
one or more polymers.
[0093] Upon expansion of the inner balloon 108 - and
thereby also the outer balloon 110 - the stent mesh 104
expands to obtain the expanded stent diameter. This re-
sults in the outer balloon 110 breaking whereby the bio-
compatible solution 112 is distributed in the openings 105
in between the stent mesh structure and around the stent
mesh.
[0094] Alternatively, the stent mesh 104 may have self-
expanding features such that the expansion of the stent
mesh 104 is not directly obtained by the expansion of the
balloons 108, 110. In that situation, the expansion will
most often occur before the expansion if the inner bal-
loon.
[0095] Upon radiation from the optical fibre, the bio-
compatible solution 112 distributed in the openings in
between the stent mesh structure and around the stent
mesh structure is adapted to create a hydrogel coating
layer 114 around the stent mesh structure (see figure 2c).
[0096] Depending on the size of the body cavity/vessel,
which the stent system 100 is to be inserted in, the size
of the cylindrical mesh 104 and the coating layer 114
formed around the mesh 104 varies.
[0097] If the stent system 100 is for being inserted into
a blood vessel, the stent is normally rather small with
expanded diameter fitting inside the blood vessel. If the
body cavity/vessel instead is an intestine, it may have a
large expanded diameter and stents for body cavities of
sizes in between that of a blood vessel and an intestine,
will expand to a middle sized expanded stent diameter
having the size of e.g. an ureteral duct.
[0098] Figures 2a-e show how a hydrogel coated stent
implanted in a body cavity/vessel 102, such as a blood
vessel, a ureteral duct or an intestine starting with the
stent system disclosed herein.
[0099] Figure 2a shows a stent system inserted in a
body cavity/vessel 102. As can be seen in the figure, the
stent mesh 104 is in the initial configuration, where the
diameter of the stent mesh is small. Also none of the
balloons 108, 110 are expanded yet. Through the cath-
eter 106 extends an optical fibre (not visible form the
figure) adapted for providing light between 10 nm - 800
nm. Normally, ultra violet, visible, or infrared light will be
provided from the fibre.
[0100] Figure 2b shows the stent system after the inner
balloon 108 - and thereby also the outer balloon 110 -
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has been expanded nearly to a first pre-determined size
at which the outer balloon 110 breaks and the biocom-
patible solution 112 is distributed in the openings 105 in
between the stent mesh structure and around the stent
mesh structure as shown in figure 2c
[0101] Figure 2c shows the stent system after the outer
balloon 110 has broken and the biocompatible solution
112 is squeezed against/around and in between the stent
mesh structure also filling some of the space between
the stent mesh 104 and the body cavity/vessel 102. The
shaping of the stent mesh 104 to match the tissue/vessel
wall 103 in the surrounding body cavity/vessel 102 by
expanding the inner balloon 108 further to obtain an ex-
panded diameter is illustrated in figure 2d. In figure 2d,
the lines symbolising the stent mesh 104 have been
drawn thicker to illustrate that the biocompatible solution
112 is now surrounding the stent mesh structure 104.
[0102] Figure 2e illustrates the final irradiation of the
biocompatible solution 112 distributed in the openings in
between the stent mesh structure and around the stent
mesh structure 104 with light between 10 nm - 800 nm
from the optical fibre extending through the catheter 106.
The irradiation process starts a polymerization and/or
cross-linking reaction of the biocompatible solution 112
which creates a hydrogel coating 114 surrounding the
stent mesh structure 104.
[0103] After the hydrogel coating 114 has been formed,
the optical fibre and the catheter 106 are removed from
the body cavity/vessel 102 thereby leaving the hydrogel
coated stent in the body cavity/vessel as shown in figure
2f.
[0104] Figure 3 shows the concentration of liposomes
labelled with fluorescein which are released over time by
different hydrogels specimens composed by a single pol-
ymer constituent or by a blend of two polymer constitu-
ents in different concentrations. In the specific example,
the abbreviation POLY1 refers to polyvinylpyrrolidone
(PVP) and the abbreviation POLY2 refers to sodium al-
ginate.
[0105] The different kinetic trends displayed in figure
3 show the cumulative release as a function of time. De-
pending on the therapeutic necessity, the release rate
may be tuned and controlled by variations of the mono-
mer/oligomer/polymer type/mixtures in the biocompati-
ble solution.
[0106] Figure 4 shows the nano scale structure of the
polyvinylpyrrolidone and sodium alginate mixture hydro-
gel network measured using Cryogenic Transmission
Electron Microscopy.
REFERENCES
[0107]
100 stent system
102 body cavity/vessel
103 wall of the body cavity/vessel
104 stent mesh
105 openings in the stent mesh
106 catheter
108 inner balloon
110 outer balloon
112 biocompatible solution
114 hydrogel coating layer around/surrounding the
stent mesh structure
Claims
1. A stent system adapted for being implanted in a body
cavity or body vessel, such as a blood vessel, a ure-
teral duct or an intestine section, the stent system
comprising a stent mesh with a stent structure, the
stent mesh having a hollow cylindrical shape ex-
pandable in diameter from an initial stent diameter
to an expanded stent diameter, the hollow cylindrical
shape comprising a plurality of openings in between
the mesh structure, wherein enclosed inside the
stent mesh and comprised further in the stent system
are:
- a catheter extending through the stent mesh,
the catheter being adapted for containing an op-
tical fibre providing radiation, e.g. in the wave-
length range between 10-800 nm;
- a biocompatible solution adapted for forming
photo-crosslinked hydrogels when exposed to
radiation from the optical fibre extending through
the catheter, the biocompatible solution com-
prising one or more monomers, and/or one or
more oligomers, and/or one or more polymers;
- an inner balloon positioned around the cathe-
ter;
- an outer balloon positioned around the inner
balloon, wherein the outer balloon contains the
biocompatible solution, the biocompatible solu-
tion filling up the space between the inner bal-
loon and the outer balloon,
wherein upon expansion of the inner balloon, the
stent mesh expands to obtain the expanded stent
diameter, and the outer balloon breaks whereby the
biocompatible solution is distributed in the openings
in between the stent mesh structure and around the
stent mesh structure,
wherein the biocompatible solution distributed in the
openings in between the stent mesh structure and
around the stent mesh structure upon radiation from
the optical fibre is adapted to create a coating layer
around the stent mesh.
2. A stent system according to claim 1, wherein the
coating layer has a thickness between 0.05 mm - 5
mm, such as between 0.1 mm - 1 mm, such as be-
tween 0.1 mm - 100 mm, such as between 0.1 mm -
10 mm, such as between 0.1 mm - 1 mm, such as
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between 1 mm - 100 mm, such as between 1 mm -
10 mm, such as between 1 mm - 5 mm, such as
between 10 mm - 100 mm, such as between 10 mm
- 500 mm, such as between 1 mm - 1 mm.
3. A stent system according to any preceding claim,
wherein the biocompatible solution comprises two
or more polymers, wherein at least one of the poly-
mers is cross-linkable upon exposure to radiation
between 10 nm - 800 nm.
4. A stent system according to any preceding claim,
wherein the biocompatible solution is polyvinylpyr-
rolidone, sodium alginate, synthetic polymers, or
naturally occurring polymers modified to be cross-
linkable upon exposure to radiation from the optical
fibre.
5. A stent system according to any preceding claim,
wherein the biocompatible solution further compris-
es one or more of the following additional substanc-
es:
• hydrogen peroxide
• benzoyl peroxide
• acetophenone
• benzoin
• 2,2-dimethoxy-2-phenylacetophenone
• dibenzoyl disulphides
• diphenyldithiocarbonate
• 2,20-azobisisobutyronitrile
• camphorquinone
• eosin Y
• triethanolamine
• 2,2-bis[4-(2-hydroxy-3-methacryloxypro-
poxy)-phenyl]propane
• lithium phenyl-2,4,6-trimethylbenzoylphosphi-
nate
• (1-[4-(2-Hydroxyethoxy)-phenyl]-2-hydroxy-2-
methyl-1-propane-1-one
• 2,20-Azobis[2-methyl-N-(2-hydroxyethyl)pro-
pionamide
• (1-hydroxycyclohexyl)-phenylmethanone.
6. A stent system according to any preceding claim,
wherein the stent system further comprises a photo
initiator/cross-linker in connection with the biocom-
patible solution, and wherein the coating layer is
formed by a radical or ionic cross-linking or polym-
erization reaction initiated by the photo initiator when
the photo initiator is exposed to radiation from the
optical fibre.
7. A stent system according to any preceding claim fur-
ther comprising one or more bioactive components
including one or more of a bioactive agent, a bioac-
tive principle, a bioactive compound, a bioactive mol-
ecule, a bioactive drug, a therapeutic agent, a ther-
apeutic principle, a therapeutic compound, a thera-
peutic molecule, and/or a therapeutic drug.
8. A stent system according to claim 7, wherein the one
or more bioactive components is a synthetic or a
natural compound of a molecular weight ranging
from 100 to 500.000 Da, such as from 1.000 to
500.000 Da, or such as from 10.000 to 500.000 Da,
or such as from 100 to 10.000 Da, or such as from
100 to 1.000 Da.
9. A stent system according to any of the claims 7-8,
wherein the one or more bioactive components in-
cludes a bioactive component for one or more of the
following:
• preventing that the immune response in the
body is activated
• preventing that the tissue in the body cavi-
ty/vessel is injured due to the stent mesh
• preventing inflammation or similar inside the
body
• postponing that the immune response in the
body is activated
• postponing inflammation or similar inside the
body.
10. A stent system according to any of the claims 7-9,
wherein the one or more bioactive components in-
cludes a therapeutically active component for:
• postponing a disease, and inflammation or sim-
ilar inside the body, and/or
• treating a disease, and inflammation or similar
inside the body.
11. A stent system according to any of the claims 7-10,
wherein the one or more bioactive components are
comprised in colloidal formulations.
12. A stent system according to claim 11, wherein the
colloidal formulations includes a colloidal drug deliv-
ery system (DDS) such as liposomes, and wherein
one or more drug components in the DDS optionally
is a hydrophobic or hydrophilic drug molecule.
13. A stent system according to any of the claims 7-12,
wherein the one or more bioactive components, pos-
sibly comprised inside the colloidal formulation, are
contained in the biocompatible solution or inside mi-
cro reservoirs in the stent mesh.
14. A stent system according to any preceding claim,
wherein the stent mesh is made from a biodegrad-
able material or a biocompatible and/or biodegrad-
able metal.
15. A stent system for use in treating a disease and/or
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an inflammation inside the body.
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